Novo Nordisk Rises as Pressure From a Low-Cost GLP-1 Rival Eases

Novo Nordisk (NVO) is up 3.6% today. Here is some analysis on what might have caused this price movement. ([uk.investing.com](https://uk.investing.com/news/stock-market-news/novo-nordisk-kroger-and-eli-lilly-rise-premarket-micron-falls-4495996?utm_source=openai))

Analysis: The move appears tied to a friendlier competitive setup in obesity care after Hims & Hers pulled back its heavily discounted compounded GLP-1 pill and shifted further toward branded, FDA-approved options. That likely reduced near-term pricing pressure around Novo Nordisk’s oral Wegovy launch and reinforced investor confidence in the company’s semaglutide franchise. ([uk.investing.com](https://uk.investing.com/news/stock-market-news/novo-nordisk-kroger-and-eli-lilly-rise-premarket-micron-falls-4495996?utm_source=openai))

Details:

Hims & Hers said it would no longer advertise compounded GLP-1 offerings broadly and would transition patients toward FDA-approved alternatives when clinically appropriate. ([investors.hims.com](https://investors.hims.com/news/news-details/2026/Hims--Hers-Announces-Strategic-Shift-for-US-Weight-Loss-Business/default.aspx?mod=article_inline))

Novo Nordisk said patients on the Hims & Hers platform would gain access to its FDA-approved semaglutide medicines, including Wegovy pill, while Novo dismissed its patent suit but kept the right to refile later. ([novomedlink.com](https://www.novomedlink.com/content/dam/novomedlink/semaglutide/03-09-2026-company-statement.pdf))

The FDA said in February it intended to restrict GLP-1 ingredients used in non-FDA-approved compounded drugs being mass-marketed as alternatives to approved medicines, which supports the branded manufacturers’ position. ([fda.gov](https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs?utm_source=openai))

A broader support factor is that Novo Nordisk raised 2026 guidance in August, citing rapid U.S. adoption of Wegovy pill and more than 5 million prescriptions since launch. ([novonordisk.com](https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916590))

Sources:

Novo Nordisk, Hims & Hers, FDA ([novomedlink.com](https://www.novomedlink.com/content/dam/novomedlink/semaglutide/03-09-2026-company-statement.pdf))

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$NVO Hedge Fund Activity

We have seen 674 institutional investors add shares of $NVO stock to their portfolio, and 783 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 6,290,535 shares (-56.6%) from their portfolio in Q2 2026, for an estimated $301,568,247
TWO SIGMA INVESTMENTS, LP removed 6,270,701 shares (-99.7%) from their portfolio in Q2 2026, for an estimated $300,617,405
FRED ALGER MANAGEMENT, LLC added 4,907,570 shares (+inf%) to their portfolio in Q2 2026, for an estimated $235,268,905
VOLORIDGE INVESTMENT MANAGEMENT, LLC removed 4,807,279 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $172,364,988
CITADEL ADVISORS LLC removed 4,674,398 shares (-63.1%) from their portfolio in Q1 2026, for an estimated $167,600,540
GOLDMAN SACHS GROUP INC added 4,059,453 shares (+79.3%) to their portfolio in Q2 2026, for an estimated $194,610,176
FRANKLIN RESOURCES INC removed 3,042,370 shares (-18.9%) from their portfolio in Q2 2026, for an estimated $145,851,217

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$NVO Congressional Stock Trading

Members of Congress have traded $NVO stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $NVO stock by members of Congress over the last 6 months:

SENATOR ALAN ARMSTRONG purchased up to $50,000 on 03/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.